Ongoing efforts toward early PCa screening utilize molecular markers, prostate-specific antigen screening, standard biopsy, magnetic resonance imaging-targeted biopsy, digital rectal examination, and transrectal ultrasound. The gene discussed is KLK3; the disease is posterior cortical atrophy.